Information Provided By: 
Fly News Breaks for July 27, 2015
XON
Jul 27, 2015 | 07:56 EDT
Wunderlich analyst Rob Breza raised his price target for Intrexon to $70 saying the company continues to expand its deal pipeline. Intrexon is a favorable investment relative to pure-play biotechs as the company boasts a larger addressable market, does not burn cash and generates a stable stream of product and services revenue, Breza tells investors in a research note. He keeps a Buy rating on the name. The synthetic biology focused company closed Friday down $1.39 to $56.86.
News For XON From the Last 2 Days
There are no results for your query XON
